BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24747415)

  • 1. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
    Saga H; Ohhata A; Hayashi A; Katoh M; Maeda T; Mizuno H; Takada Y; Komichi Y; Ota H; Matsumura N; Shibaya M; Sugiyama T; Nakade S; Kishikawa K
    PLoS One; 2014; 9(4):e93230. PubMed ID: 24747415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
    Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin and Lysophosphatidic Acid Signalling: the Pleiotropic Regulatory Network in Cancer.
    Vít O; Petrák J
    Folia Biol (Praha); 2023; 69(5-6):149-162. PubMed ID: 38583176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac.
    Koike S; Keino-Masu K; Ohto T; Sugiyama F; Takahashi S; Masu M
    J Biol Chem; 2009 Nov; 284(48):33561-70. PubMed ID: 19808661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Autotaxin and LPA Signaling in Embryonic Development, Pathophysiology and Cancer.
    Magkrioti C; Kaffe E; Aidinis V
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
    Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
    J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases.
    Cholia RP; Nayyar H; Kumar R; Mantha AK
    Curr Mol Med; 2015; 15(10):932-43. PubMed ID: 26391552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
    Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
    Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 3D view of autotaxin.
    Nishimasu H; Ishitani R; Aoki J; Nureki O
    Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.
    Pamuklar Z; Federico L; Liu S; Umezu-Goto M; Dong A; Panchatcharam M; Fulkerson Z; Berdyshev E; Natarajan V; Fang X; van Meeteren LA; Moolenaar WH; Mills GB; Morris AJ; Smyth SS
    J Biol Chem; 2009 Mar; 284(11):7385-94. PubMed ID: 19139100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of enterocyte Enpp2 and autotaxin in regulating lipopolysaccharide levels, systemic inflammation, and atherosclerosis.
    Chattopadhyay A; Mukherjee P; Sulaiman D; Wang H; Girjalva V; Dorreh N; Jacobs JP; Delk S; Moolenaar WH; Navab M; Reddy ST; Fogelman AM
    J Lipid Res; 2023 May; 64(5):100370. PubMed ID: 37059333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial ENPP2 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 2) Increases Atherosclerosis in Female and Male Mice.
    Karshovska E; Mohibullah R; Zhu M; Zahedi F; Thomas D; Magkrioti C; Geissler C; Megens RTA; Bianchini M; Nazari-Jahantigh M; Ferreirós N; Aidinis V; Schober A
    Arterioscler Thromb Vasc Biol; 2022 Aug; 42(8):1023-1036. PubMed ID: 35708027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
    Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
    Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell transcriptome dynamics of the autotaxin-lysophosphatidic acid axis during muscle regeneration reveal proliferative effects in mesenchymal fibro-adipogenic progenitors.
    Contreras O; Harvey RP
    Front Cell Dev Biol; 2023; 11():1017660. PubMed ID: 36910157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
    Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-function relationships of autotaxin, a secreted lysophospholipase D.
    Hausmann J; Perrakis A; Moolenaar WH
    Adv Biol Regul; 2013 Jan; 53(1):112-7. PubMed ID: 23069371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent inhibitors of the lysophospholipase autotaxin.
    Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Therapeutic Applications for Inhibitors of Autotaxin, a Bioactive Lipid-Producing Lysophospholipase D, in Disorders Affecting the Nervous System.
    Herr DR; Ong JH; Ong WY
    ACS Chem Neurosci; 2018 Mar; 9(3):398-400. PubMed ID: 29457888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.